CL2022000008A1 - Composiciones comprimidas de macitentán, métodos y usos de las mismas. - Google Patents

Composiciones comprimidas de macitentán, métodos y usos de las mismas.

Info

Publication number
CL2022000008A1
CL2022000008A1 CL2022000008A CL2022000008A CL2022000008A1 CL 2022000008 A1 CL2022000008 A1 CL 2022000008A1 CL 2022000008 A CL2022000008 A CL 2022000008A CL 2022000008 A CL2022000008 A CL 2022000008A CL 2022000008 A1 CL2022000008 A1 CL 2022000008A1
Authority
CL
Chile
Prior art keywords
macitentan
compositions
methods
present disclosure
effective amount
Prior art date
Application number
CL2022000008A
Other languages
English (en)
Inventor
Serra João Pedro Silva
Pereira Ricardo José Camilo Ferreira
Original Assignee
Tecnimede Soc Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico Medicinal Sa filed Critical Tecnimede Soc Tecnico Medicinal Sa
Publication of CL2022000008A1 publication Critical patent/CL2022000008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación también se refiere a composiciones comprimidas que comprenden una cantidad terapéuticamente eficaz de macitentán, un diluyente de alcohol de azúcar y un tensioactivo. También se refiere al procedimiento de obtención de dichas composiciones comprimidas, a composiciones farmacéuticas orales que las comprenden, y a su uso en el tratamiento de hipertensión arterial pulmonar. La presente divulgación también se refiere a composiciones farmacéuticas orales sólidas que comprenden una cantidad terapéuticamente eficaz de macitentán que simultáneamente presentan propiedades de estabilidad mejoradas y perfiles de disolución adecuados, lo que presenta una necesidad insatisfecha en el campo de la formulación farmacéutica de macitentán.
CL2022000008A 2019-07-05 2022-01-03 Composiciones comprimidas de macitentán, métodos y usos de las mismas. CL2022000008A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT11563219 2019-07-05
EP19185065 2019-07-08

Publications (1)

Publication Number Publication Date
CL2022000008A1 true CL2022000008A1 (es) 2022-10-07

Family

ID=71899791

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000008A CL2022000008A1 (es) 2019-07-05 2022-01-03 Composiciones comprimidas de macitentán, métodos y usos de las mismas.

Country Status (10)

Country Link
US (1) US20220249381A1 (es)
CN (1) CN114096239B (es)
AU (1) AU2020309223A1 (es)
BR (1) BR112022000117A2 (es)
CA (1) CA3144613A1 (es)
CL (1) CL2022000008A1 (es)
CO (1) CO2021017646A2 (es)
MX (1) MX2022000267A (es)
PE (1) PE20220593A1 (es)
WO (1) WO2021005478A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
EP4154873A1 (en) * 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
WO2023128898A1 (en) * 2021-12-30 2023-07-06 Humanis Saglik Anonim Sirketi Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345920B1 (en) 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
US20080233188A1 (en) 2005-09-12 2008-09-25 Actelion Pharmaceuticals Ltd. Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
CN102215847B (zh) 2008-11-17 2014-07-16 武田奈科明有限公司 碳酸钙片剂的改善的溶出稳定性
DE14721256T1 (de) 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
IN201641002749A (es) 2016-01-25 2017-09-15 Hetero Research Foundation
CN107913256A (zh) * 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CN109260163A (zh) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 一种马西替坦片剂组合物

Also Published As

Publication number Publication date
MX2022000267A (es) 2022-02-03
PE20220593A1 (es) 2022-04-22
BR112022000117A2 (pt) 2022-02-15
CN114096239B (zh) 2024-04-12
WO2021005478A1 (en) 2021-01-14
EP3993777A1 (en) 2022-05-11
CA3144613A1 (en) 2021-01-14
CO2021017646A2 (es) 2022-01-17
CN114096239A (zh) 2022-02-25
AU2020309223A1 (en) 2022-03-03
US20220249381A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
CL2022000008A1 (es) Composiciones comprimidas de macitentán, métodos y usos de las mismas.
AR111455A1 (es) Formulación estable de anticuerpo
NI202100009A (es) Métodos para reducir la necesidad de revascu
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
MY198452A (en) Sustained-release formulations of colchicine and methods of using same
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
CL2018003178A1 (es) Composición farmacéutica
CL2020002252A1 (es) Formulación oftálmica.
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
NO20084478L (no) Konjugerte lipidderivater
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
ES2600137T3 (es) Procedimiento de fabricación de composiciones proteicas de baja solubilidad, composiciones obtenidas y su utilización en los productos de panificación
MX2018011696A (es) Composición farmacéutica de dapagliflozina.
WO2017083266A8 (en) Novel formulations
CO2018010568A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2- (etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2- metilpentanoico cristalino, y sus usos
WO2009084036A3 (en) Composition for treatment of viral infections
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
UY39257A (es) Composición farmacéutica acuosa de levilimab y su uso
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
MX2020004105A (es) Formulacion farmaceutica.